Core Viewpoint - A securities class action lawsuit has been filed against StubHub Holdings, Inc. by Kessler Topaz Meltzer & Check, LLP on behalf of investors who acquired StubHub common stock during its September 2025 initial public offering, with a lead plaintiff deadline set for January 23, 2026 [1][2]. Allegations Against Defendants - The complaint alleges that the Offering Documents contained false and misleading statements, including: 1. StubHub was experiencing changes in the timing of payments to vendors 2. These changes significantly adversely impacted StubHub's free cash flow, including trailing 12 months free cash flow 3. StubHub's free cash flow reports were materially misleading 4. Defendants' positive statements about the company's business, operations, and prospects were materially false and misleading or lacked a reasonable basis [2]. Lead Plaintiff Process - Investors may seek to be appointed as a lead plaintiff representative of the class by January 23, 2026, or may choose to remain an absent class member. The lead plaintiff will act on behalf of all class members in directing the litigation and is typically the investor or small group of investors with the largest financial interest [3].

Core Viewpoint - A class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. for alleged securities fraud and unlawful business practices following disappointing financial results and a significant impairment charge [2]. Financial Performance - Alexandria reported third-quarter financial results for fiscal year 2025 that were below expectations, leading to a reduction in full-year 2025 funds from operations (FFO) guidance [2]. - The company experienced lower occupancy rates and slower leasing activity, which contributed to the financial setback [2]. - A notable real estate impairment charge of $323.9 million was reported, with $206 million attributed to its Long Island City property [2]. - Following the announcement, Alexandria's stock price fell by $14.93 per share, or 19.17%, closing at $62.94 per share on October 28, 2025 [2].

Core Viewpoint - The Perrigo Company plc is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding the financial health of its acquired infant formula business [1][3]. Group 1: Class Action Details - The class action lawsuit is titled French v. Perrigo Company plc and covers securities purchases from February 27, 2023, to November 4, 2025, with a deadline for lead plaintiff applications set for January 16, 2026 [1][2]. - The lawsuit alleges that Perrigo's acquisition of Nestlé's Gateway infant formula plant for $170 million was marred by significant underinvestment and operational deficiencies [2][3]. Group 2: Financial Implications - On February 27, 2024, Perrigo disclosed acquisition-related charges of $35 million to $45 million for remediation efforts, alongside a 50% decline in earnings per share compared to the previous year [4]. - The company reported net sales of $91 million on May 7, 2024, a decrease of 34.5%, attributed to lower shipments during remediation efforts, leading to a nearly 10% drop in stock price [5]. - On August 6, 2025, Perrigo's adjusted gross profit decreased by $30 million, or 6.9%, with a reported gross margin of 34.4%, resulting in an 11% decline in stock price [6]. - On November 5, 2025, Perrigo announced a strategic review of its infant formula business, slashing its fiscal year 2025 outlook, including a net sales growth guidance adjustment from 0%-3% to -2.5% to -3% and adjusted diluted earnings per share from $2.90-$3.10 to $2.70-$2.80, causing a 25% drop in stock price [7].

Nov 26, 2025 1:45 PM Eastern Standard Time ARE Investors Have Opportunity to Lead Alexandria Real Estate Equities, Inc. Securities Fraud Lawsuit with the Schall Law Firm Share LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Alexandria Real Estate Equities, Inc. ("Alexandria†or "the Company†) (NYSE: ARE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated t ...

Core Viewpoint - A securities class action lawsuit has been filed against Firefly Aerospace Inc. for allegedly making false and misleading statements regarding its business operations and growth prospects during its IPO and subsequent period [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Firefly's common stock during the IPO on August 7, 2025, and those who acquired securities between August 7, 2025, and September 29, 2025 [1]. - The lead plaintiff deadline for the lawsuit is set for January 12, 2026 [1]. Group 2: Allegations Against Defendants - The complaint alleges that Firefly overstated the demand and growth prospects for its Spacecraft Solutions offerings [2]. - It is claimed that the Alpha rocket program did not meet its operational readiness and commercial viability as represented [2]. - As a result of these issues, the statements made by the defendants regarding the company's business and prospects were materially false and misleading [2]. Group 3: Lead Plaintiff Process - Investors may seek to be appointed as a lead plaintiff representative of the class by the January 12, 2026 deadline or may choose to remain absent [3]. - The lead plaintiff will act on behalf of all class members and select counsel to represent the class [3].

Core Viewpoint - Stride, Inc. is facing a securities class action lawsuit from shareholders due to significant operational and compliance challenges that have led to a sharp decline in its stock price [1] Company Overview - Stride, Inc. is one of the largest providers of online educational services in the United States [1] Legal Proceedings - Hagens Berman, a prominent shareholder rights law firm, is investigating legal claims against Stride and its executives, urging affected investors to report their losses [2] - The class action lawsuit covers the period from October 22, 2024, to October 28, 2025, with a lead plaintiff deadline set for January 12, 2026 [3] Allegations - The lawsuit focuses on Stride's misleading assurances regarding its business model and enrollment figures, particularly after the cancellation of a contract with Gallup-McKinley [3] - Allegations include inflated student enrollment numbers through "ghost students," increased student-to-teacher ratios, and insufficiently licensed teachers, all aimed at inflating stock values [4][8] Impact on Enrollment - Stride reported that "poor customer experience" led to an estimated loss of 10,000 to 15,000 enrollments [5] Financial Forecast - The company has forecasted a sales growth of only 5% for 2026, a significant decline from the previous five years' annualized sales growth of 19%, raising concerns among investors [6] Investigation Focus - The investigation aims to determine the extent of company leadership's awareness of operational and compliance deficiencies prior to public disclosures and whether these misrepresentations constitute securities fraud [7]

Core Viewpoint - MoonLake Immunotherapeutics has faced a significant decline in share price, dropping nearly 90% in one day due to disappointing Phase 3 trial results for its drug candidate sonelokimab (SLK) [1][5]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing SLK, which is intended to treat moderate to severe hidradenitis suppurativa (HS), a chronic inflammatory skin disease [3]. Legal Issues - A securities fraud class action lawsuit has been filed against MoonLake in the U.S. District Court for the Southern District of New York, alleging that the company and certain executives made materially false and misleading statements regarding SLK's clinical prospects [2][4]. - The lawsuit claims that MoonLake exaggerated SLK's benefits over competitors, particularly in relation to its unique "Nanobody" structure, which was presented as a major competitive advantage [4][6]. Trial Results - The VELA Phase 3 trials, particularly VELA-2, did not meet their primary endpoint, leading to a significant drop in stock price from $61.99 to $6.24, a decrease of $55.75 per share [5]. - Analysts noted that the efficacy results from the successful trial were substantially lower than those achieved by the competitor drug BIMZELX, which shares the same molecular targets [4][6]. Investor Impact - The decline in stock price has prompted Hagens Berman, a plaintiffs' rights firm, to investigate claims of misleading information that may have artificially inflated the stock price during the class period from March 10, 2024, to September 29, 2025 [2][6].

Core Viewpoint - aTyr Pharma, Inc. is facing intensified financial and legal pressures following disappointing third-quarter results that missed Wall Street estimates, alongside ongoing securities class action litigation related to misleading information about its drug Efzofitimod [1][5]. Financial Performance - aTyr reported a GAAP EPS loss of -$0.26 for Q3, missing analyst consensus estimates by $0.08 [3]. - The company's revenues were reported at $190,000, indicating a heavy reliance on its clinical pipeline rather than commercial sales [3]. Clinical Developments - Despite the disappointing results from the Phase 3 EFZO-FIT study, aTyr plans to meet with the U.S. FDA in Q1 2026 to discuss the study results and the future of Efzofitimod in treating pulmonary sarcoidosis [4]. - The EFZO-FIT study did not meet its primary endpoint, leading to a significant market reaction with the stock price dropping over 83% in one day, from $6.03 to $1.02 [6]. Legal Issues - The ongoing securities class action litigation alleges that aTyr and its executives provided materially false and misleading information regarding Efzofitimod's efficacy [5]. - The class action period has been expanded to include investors who acquired shares between November 7, 2024, and September 12, 2025, with claims that the company concealed deficiencies in the drug's performance [7]. - Hagens Berman is investigating whether aTyr misled investors about its data and trial design while promoting Efzofitimod's market potential [8].

Core Viewpoint - A class action lawsuit has been filed against Synopsys, Inc. for securities fraud following a significant stock drop due to potential violations of federal securities laws [2][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of California, titled Kim v. Synopsys, Inc., et al., No. 3:25-cv-09410 [4]. - Investors have until December 30, 2025, to request to be appointed to lead the case [4]. Group 2: Company Performance and Allegations - Synopsys provides design automation software and has seen its Design IP segment grow from 25% of revenue in 2022 to 31% in 2024 [5]. - The company previously claimed that customers relied on its IP to minimize integration risk and noted strength in Europe and South Korea [6]. - Allegations state that customers began requiring more customization for IP components, negatively impacting the economics of the Design IP business [6]. Group 3: Financial Impact - On September 9, 2025, Synopsys reported Q3 2025 results, revealing a 7.7% year-over-year decline in Design IP revenue to $425.9 million and a 43% year-over-year decline in net income to $242.5 million [7]. - Following the release of these results, Synopsys stock fell nearly 36%, from $604.37 per share to $387.78 per share [7].

Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. for securities fraud, following significant stock drops attributed to alleged violations of federal securities laws [2][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Eastern District of Virginia, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [4]. - Investors have until January 12, 2026, to request to lead the case [4]. Group 2: Allegations Against Stride - Stride, an education technology company, allegedly inflated enrollment numbers by retaining "ghost students" and ignored compliance requirements, leading to a poor customer experience [5]. - The company claimed to be experiencing growth and high demand, which is contradicted by the allegations of inflated enrollment figures and high withdrawal rates [5]. Group 3: Stock Performance Impact - On September 14, 2025, a report of the lawsuit caused Stride's stock to drop by $18.60, or over 11%, from $158.36 to $139.76 per share [6]. - Following an admission of poor customer experience on October 28, 2025, Stride's stock plummeted by $83.48, or more than 54%, from $153.53 to $70.05 per share [7].